June 2026 Roche expanded its influenza portfolio by strengthening U.S. commercial initiatives for Xofluza® (baloxavir marboxil), supporting broader access to single-dose influenza treatment during the seasonal flu period.
May 2026 Pfizer Inc. expanded research collaborations focused on next-generation antiviral therapies for respiratory viral infections, including influenza, to accelerate future treatment innovation.
March 2026 Shionogi & Co., Ltd. advanced the development of novel antiviral candidates targeting influenza viruses through expanded global clinical research programs.
August 2025 Genentech strengthened collaborations with U.S. healthcare organizations to improve awareness of early influenza diagnosis and timely antiviral treatment.